Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of securities of Stride, Inc. for the period between October 22, 2024, and October 28, 2025, due to alleged misleading statements and omissions regarding the company's products and services [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Stride made misleading statements about its products and services aimed at educational institutions, while inflating enrollment numbers and cutting staff costs beyond statutory limits [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by January 12, 2026, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Insights - Seabridge Gold Inc. maintains a strong financial position with cash and cash equivalents of $103.1 million as of 3Q25, bolstered by a US$100.2 million equity financing in February 2025 and a $30.5 million flow-through financing in June 2025 [1][7] - The company is focused on advancing its flagship KSM project and exploration activities at Iskut, 3 Aces, and Snowstorm [1] - Seabridge has renewed its US$750 million base shelf prospectus and US$100 million ATM facility in early 2025 [1] Financial Position - Cash and cash equivalents stand at $103.1 million at the end of the quarter [7] - Secured note liabilities amount to $583.1 million, which supports ongoing programs [7] Project Developments - The KSM project is advancing towards partnership and feasibility, with Treaty Creek substation construction on schedule for 4Q26 and field programs progressing towards a bankable study [7] - Drilling at Iskut Snip North has confirmed a significant Cu Au porphyry, including 819.7 meters at 0.66 g/t Au and 0.14% Cu, with a maiden resource targeted for 1Q26 [7]

Core Points - LevelJump Healthcare Corp. has called an annual and special meeting of shareholders to be held on May 26, 2026, in response to a requisition from certain shareholders seeking to remove all current directors and appoint five new directors [1][2]. Group 1: Meeting Details - The Board decided to hold a single shareholder meeting to address both annual business and the requisition matters, which is the earliest date for audited financial statements to be available for consideration [2]. - This approach is seen as a prudent use of shareholder capital, avoiding the costs associated with holding separate meetings in close proximity [2]. - Shareholders will receive further details about the meeting and voting procedures in a management information circular prior to the meeting [3]. Group 2: Company Overview - LevelJump Healthcare Corp. provides telehealth solutions through its Teleradiology division and in-person radiology services via its Diagnostic Centres, focusing on critical care for urgent and emergency patients [5].

Core Insights - Electromed, Inc. will participate in NobleCon21, an emerging growth equity conference, on December 3, 2025, where CEO Jim Cunniff will present [1] - A video webcast of the presentation will be available on Electromed's website the following day [2] - Electromed specializes in airway clearance therapy products, including the SmartVest® Airway Clearance System, and was founded in 1992 [3] Company Overview - Electromed, Inc. is headquartered in New Prague, Minnesota, and focuses on manufacturing and marketing airway clearance therapy products [3] - The company has a history dating back to 1992 and aims to assist patients with compromised pulmonary function [3] Conference Details - NobleCon21 is organized by Noble Capital Markets, a full-service broker-dealer established in 1984, which provides investment and advisory services [4] - Noble Capital Markets has raised billions for companies and published over 45,000 equity research reports [4]

Core Viewpoint - Smith & Wesson Brands, Inc. plans to release its second quarter fiscal 2026 financial results on December 4, 2025, after market close [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call and webcast on the same day, featuring Mark Smith (President and CEO) and Deana McPherson (Executive VP and CFO) [2] - The conference call is scheduled to begin at 5:00 p.m. Eastern Time [2] Group 2: Participation Details - Interested parties in North America can join by dialing 1-877-704-4453, while international participants can call 1-201-389-0920 [3] - Participants are advised to dial in at least 10 minutes prior to the start of the call [3] Group 3: Company Overview - Smith & Wesson Brands, Inc. is a leader in firearm manufacturing and design, offering a wide range of products including handguns, long guns, and suppressors [4] - The company also provides manufacturing services and firearm training programs through the Smith & Wesson Academy in Maryville, TN [4]

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to alleged violations of federal securities laws [2][4]. Company Overview - Stride, Inc. is an education technology company that provides an online platform to students across the U.S. [5]. Allegations and Stock Impact - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students" and ignored compliance requirements, leading to a poor customer experience and higher withdrawal rates [5][6]. - On September 14, 2025, a report of fraud allegations caused Stride's stock to drop by $18.60, or over 11%, from $158.36 to $139.76 per share [6]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48, or more than 54%, from $153.53 to $70.05 per share, with an estimated impact of 10,000-15,000 fewer enrollments [7]. Legal Context - Investors have until January 12, 2026, to seek appointment as lead plaintiffs in the case, which is pending in the U.S. District Court for the Eastern District of Virginia [4]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. Legal Representation - Bleichmar Fonti & Auld LLP is representing the plaintiffs in this class action and has a history of successful recoveries in similar cases [10].

INSP INVESTORS: BFA Law Reminds Inspire Medical Systems, Inc. Investors with Losses to Contact the Firm Before the Imminent January 5 Securities Class Action DeadlineNovember 20, 2025 3:46 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for s ...

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and certain senior executives for potential violations of federal securities laws, with a deadline for investors to join the case by December 15, 2025 [2][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [5]. Allegations and Clinical Data - The lawsuit alleges that MoonLake misrepresented its clinical data, claiming superior clinical benefits of SLK over competitors, which was not substantiated [6][7]. - The company's assertions about SLK's Nanobody structure being beneficial compared to traditional monoclonal antibodies are also called into question [6]. Stock Performance and Impact - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [8].

Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Arizona, titled Reed v. Freeport-McMoRan Inc., et al., No. 2:25-cv-04243, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [4]. - Investors have until January 12, 2026, to request to be appointed to lead the case [4]. Group 2: Company Operations and Safety Claims - Freeport-McMoRan operates the Grasberg Copper and Gold Mine in Indonesia, where it has been accused of overstating its commitment to safety while conducting unsafe mining practices [5][6]. - The company had previously promoted its safety procedures, including the use of data and technology to prevent fatal incidents [5]. Group 3: Stock Price Impact - On September 9, 2025, Freeport's stock dropped by $2.77 per share (over 5.9%) following a press release about suspended mining operations due to a landslide [7]. - Following updates on September 24, 2025, regarding fatalities and operational suspensions, the stock fell by $7.69 per share (almost 17%) [8]. - Additional reports on September 25, 2025, regarding strained relations with the Indonesian government led to a further decline of $2.33 per share (over 6%) [10]. - A report on September 28, 2025, indicated that the landslide was preventable, further impacting investor confidence [11].

Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws due to improper accounting practices related to accounts receivable and professional liability reserves [2][3]. Financial Performance - On November 12, 2025, Ardent reported a $43 million decrease in revenue for Q3 2025 after conducting evaluations of historical collection trends [4]. - The company also increased its professional liability reserves by $54 million due to adverse claim developments from 2019 to 2022 and broader industry trends [4]. Stock Market Reaction - Following the financial report, Ardent's stock price dropped over 33% during trading on November 13, 2025 [4]. Legal Implications - Investors in Ardent Health are encouraged to seek legal options due to the ongoing investigation and potential losses incurred [5][7]. Law Firm Background - Bleichmar Fonti & Auld LLP is a leading law firm specializing in securities class actions and has a strong track record, including recovering over $900 million from Tesla's Board of Directors [6].